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Background: Sepsis is a common disease that continues to increase in incidence in the world. Diseases, such as
diabetes mellitus, may make the situation worse. Diabetic patients are at increased risk for common infections. This
study was designed to investigate the role of glibenclamide on myocardial injury by lipopolysaccharides (LPS) in
streptozotocin induced diabetic mice (STZ-mice).
Methods: LPS was used to induce endotoxemia in STZ-mice. Heart rate and mean arterial pressure were measured
by MPA-HBBS. Serum epinephrine level was measured by enzyme-linked immunosorbent assays (ELISA). Myocardial
injury was examined by light and transmission electron microscope and TUNEL staining. Macrophage infiltration
was measured by immunohistochemistry. Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) levels in
myocardial tissue and serum in STZ-mice, and in conditional medium of primary cultured peritoneal macrophages
were determined by ELISA. Nalp3 and Caspase-1 protein levels were measured by Western blotting analysis.
Results: STZ administration decreased body weight and increased blood glucose in C57BL/6 mice. LPS injection
caused decreases of heart rate and mean arterial pressure, and elevated serum epinephrine level in C57BL/6 mice.
Compared with control mice without STZ treatment, LPS induced more severe myocardial injury and macrophage
infiltration in STZ-mice, which was attenuated by pretreatment of glibenclamide. LPS stimulation enhanced the
levels of IL-1β and TNF-α in both cardiac tissue and serum. Glibenclamide pretreatment significantly inhibited the
serum levels of pro-inflammatory cytokines. Either high glucose or LPS increased the levels of IL-1β and TNF-α in
the conditional medium of peritoneal macrophages. Glibenclamide treatment suppressed the increase of IL-1β level
induced by high glucose and LPS. Furthermore, Nalp3 and Caspase-1 levels were markedly increased by high
glucose plus LPS, and both proteins were significantly inhibited by glibenclamide treatment.
Conclusions: We conclude that glibenclamide could attenuate myocardial injury induced by LPS challenge in
STZ-mice, which was possibly related to inhibiting inflammation through Nalp3 inflammasomes.
Keywords: Glibenclamide, Lipopolysaccharides, Myocardium injury, Diabetes mellitus, Inflammation* Correspondence: fumingshen@hotmail.com; jiangguojun999@hotmail.com
†Equal contributors
2Department of Pharmacy, Shanghai Tenth People’s Hospital, Tongji
University, Shanghai 200072, China
1Department of Pharmacy, Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang
311202, China
© 2014 Jian et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Cai et al. Cardiovascular Diabetology 2014, 13:106 Page 2 of 11
http://www.cardiab.com/content/13/1/106Introduction
Septic shock induced by bacteremia is one of the leading
causes of death in critical patients. The mortality of sep-
tic shock ranges from 37% to 47% [1]. Activation of in-
flammatory factors in septic shock always occurs as a
simultaneous immune response program initiated early
in the course of the disease. Such as endotoxemia, this
occurs frequently in septic shock, cause to hemorrhages,
necrosis of the kidneys, and myocardial dysfunction. To
the final stage, the progressive systemic organ failures
may be developed due to interaction between the severe
infection and the hyperactive inflammatory response
during septic shock [2].
Lipopolysaccharide (LPS) is considered the principal
cause responsible for the heart failure in sepsis shock. LPS
may trigger acute and chronic inflammation, leading to
immune cell activation and cytokine release [3]. In endo-
toxemia, hyperactivation of the immune response leads to
the excessive production of various pro-inflammatory cy-
tokines (IL-1β and TNF-α) and cellular injury [4], which
also can result in a systemic inflammatory response and
eventually lead to multiple organ failure and death. How-
ever, the precise mechanisms responsible for myocardial
dysfunction in the setting of endotoxemia are not fully
elucidated [5].
Diabetes mellitus is a group of metabolic disorders
characterized by hyperglycaemia resulting from defects
in insulin secretion, insulin action or both [6]. With a
disease rate of 8.3% and cost of $174 billion, there is no
debate that diabetes mellitus is a highly prevalent and
costly lifelong disease [7]. It was well-established that all
patients with diabetes mellitus were at increased risk for
bacterial infections. Moreover, diabetes mellitus was as-
sociated with a poorer prognosis among the patients
with bacteremia [8]. Therefore, further studies are war-
ranted to manifest the relation between infection and
diabetes mellitus, and to deliver more effective manage-
ment of infections in diabetic patients [9].
Glibenclamide, an ATP-sensitive potassium channel
(KATP) blocker, is the most widely used sulfonylurea drug
for the treatment of type 2 diabetes mellitus in the United
States [10]. It has been shown that glibenclamide sup-
pressed neutrophil migration and chemotaxis during in-
flammatory responses via blocking KATP channel [11].
Previously glibenclamide was reported to be able to re-
duce shock-induced overproduction of pro-inflammatory
cytokines during simulated in vivo endotoxinaemia [12].
Importantly, Mohamed et al. reported that glibenclamide
prevented activation of the Nalp3 inflammasomes [13].
Nalp3 is an essential component of inflammasomes trig-
gered by pathogen-associated molecular patterns, danger-
associated molecular patterns, and crystalline substances
[14-17]. Inflammasomes activate Caspase-1 for processing
and secretion of the cytokines IL-1β and TNF-α [17].Inappropriate Nalp3 activity has been incriminated in the
pathogenesis of several diseases, including gouty arthritis,
Alzheimer’s and silicosis [18-20]. Thus, inhibition of the
Nalp3 inflammasomes may offer considerable therapeutic
promise in inflammatory-associated disease [13]. With
LPS induced endotoxemia in STZ-mice, in the present
study, we hypothesized that glibenclamide could attenuate
myocardial injury through inhibiting inflammation by pre-
venting activation of Nalp3 inflammasomes.
Materials and methods
Animals
Male C57BL/6 mice weighing 20 g, about 7 weeks of
age, obtained from the SLAC Laboratory Animal Co.,
Ltd. (Shanghai, China). The animals were maintained at
23°C ± 2°C under a cycle of 12 h light/12 h darkness
with free access to food and water. All the animals used
in this study received humane care in compliance with
the institutional animal care guidelines and the Guide
for Care and Use of Laboratory Animals published by
the National Institutes of Health.
STZ-induced diabetic mice
Animals were intraperitoneally injected with a single
dose of STZ (Amresco, USA) at 60 mg/kg body weight,
dissolved in 0.1 mM sodium citrate buffer (pH 4.5) [21].
On the fifth day after STZ administration, whole blood
was obtained from the mice tail vein and glucose levels
were measured using the blood glucose monitoring sys-
tem (MAJOR, Taiwan). For the present study, hypergly-
cemia is defined as a blood glucose measurement of
20 mM or higher. Citrate buffer-treated mice were used as
a normoglycemic control (blood glucose < 12 mM). The
STZ-mice were randomly divided into 3 groups: hypergly-
cemic mice treated with vehicle and glibenclamide-treated
mice (per day, 5 or 20 mg/kg, i.g, ×14 d) [11,22,23].
Endotoxemia model
The endotoxemia was induced by administration of LPS
(15 mg/kg, Escherichia coli 0111:B4, Cat. L2630, lot
028 K4090; Sigma-ALDRICH, USA). Six hours after in-
traperitoneal LPS injection, heart rate and mean arterial
pressure were recorded using MPA-HBBS (Shanghai
Alcott Biotech CO., LTD, Shanghai, China), as previously
described [24]. Serum epinephrine, IL-1β and TNF-α
were measured with commercially available ELISA kits
(epinephrine: Cloud-Clone Corp, Lot:L140404193, Wuhan,
China; IL-1β and TNF-α: R&D Systems, Minneapolis, MN,
USA) [25].
Morphological analysis
For histopathological observation, the mice were sacri-
ficed at 6 h after LPS injection. Heart tissues were fixed
in 10% formalin, embedded in paraffin, sectioned, and
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phological analysis. Transmission electron microscope
studies were performed as previously described [5].
Tissues were fixed with 2.5% glutaraldehyde in 0.1 mol/
l cacodylate buffer, pH 7.4, for 1 h at 4°C. After rinsing
in cacodylate buffer, tissues were postfixed in 1%
cacodylate-buffered osmium tetroxide for 2 h at room
temperature, and then dehydrated in a graded series of
ethanol, transferred to propylene oxide, embedded in
Epon-Araldite. Ultrathin sections (60-to-80-nm thick)
were cut with a diamond knife, placed on formvar car-
bon–coated copper grids (200 mesh), and stained with
uranyl acetate and lead citrate. Morphometric analyses
were observed with a Hitachi H-800 Transmission
Electron Microscope (Hitachi, Japan) [26,27].
Apoptotic analysis
Terminal deoxynucleotidyl-transferase-mediated dUTP-
nick-end labeling (TUNEL) staining was performed on
formalin-fixed, paraffin-embedded sections with a com-
mercial kit (Boehringer Mannheim, Mannheim, Germany)
according to the instructions. Briefly the sections were
first deparaffinized with xylene and ethanol and slides
rinsed twice with phosphate buffered saline (PBS),
treated 15 min with 20 mg/ml proteinase K (Boehringer
Mannheim) in 0.1 mol/L Tris–HCl buffer (pH 7.4), then
again rinsed twice with PBS. After adding the total vol-
ume (50 μl) of enzyme solution (TdT) to the remaining
450 μl of labeled solution (dUTP) to obtain 500 μl
TUNEL reaction mixture, each sample was incubated
with 50 μl TUNEL reaction mixture at 37° for 60 min
and the slides rinsed three times with PBS. After drying,
the sample was incubated with 50 μl converter-peroxidase
(POD) at 37°C for 30 min and slides were rinsed three
times with PBS. Then, 50 μl diaminobenzidine (DAB) sub-
strate was added and the sample incubated for a further
10 min at 20°C before again rinsing slides three times with
PBS. Omission of the TdT enzyme in the TUNEL reaction
was used as a negative control and resulted in no staining.
Apoptosis was evaluated by computer-assisted image
analysis system (LEICA QUIPS, LEICA Imaging Sys-
tems LTD, England) and the results were calculated as
the number of positive-staining nuclei per 1,000 cells.
For these counts, 2,000 cells were randomly selected
from each specimen [28].
Immunohistochemical staining
The infiltration of macrophages was assessed using immu-
nohistochemical assays. Sections (2 μm) were dewaxed,
incubated with 3% H2O2, blocking serum, and thereafter
with a polyclonal antibody against CD68 (Wuhan goodbio
technology CO., LTD, GB13067-1, China) at 1:500 dilu-
tion. The sections were rinsed with TBST and biotinylated
secondary antibody against rabbit IgG (KPL, 074–1506)for CD68 in a 1:200 dilution. After rinsing with TBST, the
sections were incubated with HRP-conjugated streptavidin
solution (Dako). HRP labeling was detected using a perox-
ide substrate solution with 0.8 mmol/L DAB and 0.01%
H2O2. The sections were counterstained with hematoxylin
before being examined under a light microscope. Image
Pro Plus 6.0 software was used to transfer the interes-
ting area staining density to an integrated optical den-
sity (IOD) which reflected the staining level of the area
of interest [29-31].
Measurement of IL-1β and TNF-α in heart tissue and
serum
Mice were anesthetized with an intraperitoneal injection
of sodium pentobarbital (100 mg/kg). Blood samples and
myocardial tissues were collected immediately. To meas-
ure cytokine, approximately 50 mg of cardiac tissue was
transferred to a tube, homogenized in 1,000 μl Phos-
phate Buffer Solution, and then centrifuged at 3,500 rpm
for 15 min at 4°C temperature, after which the upper
layer was collected for further analysis. Blood samples
were centrifuged (1,500 rpm for 10 min) and then super-
natants were stored as serum at − 80°C used for analysis.
IL-1β and TNF-α were measured by using commercially
available enzyme-linked immunosorbent assay (ELISA)
kits.
Measurement of IL-1β and TNF-α in the supernatant of
primary peritoneal macrophages
The concentrations of cytokine in the supernatant were
measured by ELISA. Briefly, three mice were injected with
1 ml of thioglycollate broth (3% w/v) (Sigma, 70157) days
before harvesting peritoneal macrophages by washing the
cavities with 4 ml of PBS for two times. Four hours later,
24-well culture plates were washed with 1640 medium to
remove lymphocytes. Peritoneal macrophages were resus-
pended in RPMI 1640 cell culture medium cultivated in
plates for 24 h in a 37°C humidified incubator to allow
macrophages to attach to the surface [32]. Macrophages
were incubated with high glucose (33 mM), or high glu-
cose + LPS (1 μg/ml) [29,33], or high glucose + LPS + glib-
enclamide (100 μM). Cells incubated without drug
treatment served as control. The supernatants were col-
lected 24 h later, and IL-1β and TNF-α were measured.
Western blot analysis
The lysates (50 μg of protein) were boiled for 10 min
and electrophoresed on a 12% SDS-PAGE electrophor-
esis. The membranes were incubated in PBS containing
5% non-fat dry milk for 4 h at 25°C. The blots were then
incubated for 4 h at 25°C with primary antibodies for
Nalp3 (1:1,000; Abcam, HK) and Caspase-1 (1:200;
SANTA CRUZ, USA), and then incubated with IRDye
800CW-conjugated goat anti-rabbit secondary antibody
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fluorescence image was obtained using Odyssey infrared
imaging system (Li-Cor Bioscience, Lincoln, NE), and the
band were quantified by Image J software (NIH, USA).
Statistical analysis
Data are presented as mean ± SEM and analyzed by
ANOVA followed by the Tukey-Kramer multiple com-
parisons test when appropriate. P < 0.05 was considered
statistically significant.
Results
Glibenclamide did not modify body weight and blood
glucose level in STZ-mice
As shown in Figure 1, mice were rendered diabetic by
the injection of STZ (60 mg/kg, i.p, ×5 d), and then ad-
ministered by oral gavage glibenclamide (5 mg/kg) for
14 days. Compared with control, STZ-mice exhibited a
significant reduction in body weight (18.7 ± 0.4 g vs 24.7 ±
0.1 g, P < 0.01) and elevation in blood glucose level (492 ±
20.6 mg/dl vs 147 ± 3.6 mg/dl, P < 0.01). Glibenclamide
(5 mg/kg, ×14d) did not change body weight and bloodFigure 1 Glibenclamide did not modify body weight and blood
glucose in streptozotocin (STZ) mice. Compared with control,
mice treated with STZ (60 mg/kg, i.p) displayed lower body weight
and higher blood glucose, glibenclamide (5 mg/kg, i.g, × 14 d) did
not change body weight and blood glucose in diabetic mice.
**P < 0.01. Values are means ± SEM (n = 8–10 per group).glucose level of STZ-mice (weight: 18.9 ± 0.6 g; blood glu-
cose: 484 ± 13.2 mg/dl, n = 8–10). In addition, oral gavage
glibenclamide (5 and 20 mg/kg) for 14 days in normal mice
did not change the body weight (23.9 ± 0.6 g vs 23.6 ± 0.2,
P > 0.05) and blood glucose level (155 ± 8.9 mg/dl vs 159 ±
3.5 mg/dl, P > 0.05) (Additional file 1: Figure S1, n = 5).
Glibenclamide attenuated myocardial injury by LPS in
STZ-mice
Histological analyses were performed 6 h after LPS stimula-
tion. STZ + LPS mice displayed the most serious myocar-
dial injury, including irregular arrangement, degeneration
of cardiocytes and rupture of myocardial fibers. Glib-
enclamide treatment attenuated myocardial injury in
STZ + LPS mice. Consistent with the results from light
microscopy, transmission electron microscopic ana-
lysis showed similar phenomena: the mitochondria of
cardiocytes in STZ + LPS mice showed vacuolization
and irregular swelling, accompanied by partial myofi-
bers dissolving. Glibenclamide treatment relieved all
these changes (Figure 2, n = 3). In addition, in our
study, LPS injection caused decreases of heart rate and
mean arterial pressure, and elevated serum epineph-
rine level in mice (Additional file 2: Figure S2, n = 5).
Glibenclamide attenuated myocardial apoptosis by LPS in
STZ-mice
Myocardial apoptosis was examined by TUNEL staining.
Apoptotic cells were only occasionally found in the heart
of control mice. LPS and STZ + LPS injection caused ob-
vious apoptosis (17.6 ± 1.76% and 25.9 ± 3.5% respect-
ively, P < 0.01). Glibenclamide treatment significantly
reduced the number of apoptotic cells (14.0 ± 2.3%, P <
0.01) (Figure 3, n = 3).
Glibenclamide decreased macrophage infiltration in the
cardiocytes by LPS in STZ-mice
Macrophage infiltration was measured by CD68 strain-
ing. CD68 positive area rarely appeared in cardiac tissue
of in control mice. Both STZ and LPS injection caused
infiltration of CD68 positive cells (1.67 ± 0.1 fold, P <
0.05; 2.02 ± 0.1 fold, P < 0.01). The CD68 positive area in
the STZ + LPS group was significantly increased com-
pared with that in the control group (5.28 ± 0.2 fold, P <
0.01), whereas glibenclamide treatment inhibited this ef-
fect (1.56 ± 0.2 fold vs 5.28 ± 0.2 fold, P < 0.01) (Figure 4,
n = 3).
Glibenclamide did not alter the IL-1β and TNF-α levels by
LPS in cardiac tissue of STZ- mice
LPS injection induced significant increase of IL-1β and
TNF-α levels in non-STZ mice (IL-1β: 2.12 ± 0.5 fold,
TNF-α: 4.09 ± 1.2 fold, P < 0.05). In STZ-mice, LPS in-
duced much higher level of IL-1β and TNF-α (2.83 ± 0.2
Figure 2 Morphological analysis of myocardial damage 6 h after LPS administration. Representative light and transmission electron
micrographs of the myocardial tissues indicated that LPS induced more severe myocardial injury in streptozotocin (STZ) diabetic mice, which
could be attenuated by glibenclamide (5 mg/kg, i.g, × 14 d) pretreatment. A–E, Hematoxylin-eosin stain ( × 200; n = 3 per group). A: Control, B:
STZ, C: LPS, D: S TZ + LPS, E: STZ + LPS + Glib 5 mg/kg. a–e, Transmission electron microscopy ( × 12000; n = 3 per group). a: Control, b: STZ,
c: LPS, d: STZ + LPS, e: STZ + LPS + Glib 5 mg/kg. Arrow indicates mitochondria vacuolization and myofilament dissolving. M, mitochondria;
MF, myofiber.
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non-STZ mice (Figure 5, n = 8). Glibenclamide treatment
did not change the IL-1β or TNF-α levels in STZ-mice
(Figure 5 and Additional file 3: Figure S3, n = 6–8).
Glibenclamide inhibited serum IL-1β and TNF-α levels by
LPS in STZ-mice
LPS stimulation induced significant increases of IL-1β
(7.96 ± 0.8 fold, P < 0.01) and TNF-α (6.09 ± 0.7 fold, P <
0.05) levels in non-STZ mice. In STZ-mice, LPS induced
greater levels of IL-1β (10.6 ± 0.7 fold), which was sig-
nificantly decreased by glibenclamide administration
(5.89 ± 0.8 fold, P < 0.05). After LPS stimulation TNF-α
level in STZ-mice reached 9.35 ± 1.1 fold compared to
that in non-STZ mice (P < 0.05). Similar to IL-1β, gliben-
clamide treatment significantly inhibited TNF-α expres-
sion induced by LPS in STZ-mice (7.97 ± 0.8 fold, P <
0.01) (Figure 6, n = 8–10). Compared with LPS + STZ +Glib (5 mg/kg) group, glibenclamide (20 mg/kg) treat-
ment did not change IL-1β or TNF-α level in STZ-mice
(IL-1β: 8.23 ± 0.4 fold, TNF-α: 9.61 ± 0.6 fold, Additional
file 3: Figure S3, n = 6–8).
Glibenclamide inhibited IL-1β expression by high glucose
and LPS in cultured primary peritoneal macrophages
LPS treatment induced significant increase of IL-1β
(6.19 ± 0.4 fold, P < 0.01) and TNF-α (16.4 ± 1.9 fold,
P < 0.01) levels in cultured primary peritoneal macro-
phages. High glucose alone induced significant in-
crease in both IL-1β (3.33 ± 0.5 fold, P < 0.05) and
TNF-α (5.01 ± 1.3 fold, P < 0.05) level in cultured
primary peritoneal macrophages. IL-1β levels were
significantly higher (10.5 ± 0.3 fold, P < 0.01) in high
glucose with LPS treated cultured cells than that
was only treated with LPS (6.18 ± 0.4 fold). Glibencla-
mide pretreatment only significantly decreased IL-1β
Figure 3 Glibenclamide inhibited myocardial apoptosis in streptozotocin (STZ) mice after LPS administration. Representative TUNEL
staining micrographs of the myocardial tissues indicated that LPS induced more severe injury in STZ diabetic mice, which could be attenuated by
glibenclamide (5 mg/kg, i.g, × 14 d) pretreatment. A–E, TUNEL staining ( × 200; n = 3 per group). A: Control, B: STZ, C: LPS, D: STZ + LPS, E: STZ + LPS +
Glib 5 mg/kg. **P < 0.01 vs control, #P < 0.05 vs STZ + LPS. Values are means ± SEM.
Figure 4 Glibenclamide inhibited macrophage infiltration in streptozotocin (STZ) mice after LPS administration. Representative
immunohistochemical staining micrographs for CD68 (brown) of the myocardial tissues indicated that LPS induced more macrophage infiltration
in STZ diabetic mice, which could be attenuated by glibenclamide (5 mg/kg, i.g, × 14 d) pretreatment. (A–E), Immunohistochemical staining for
CD68 ( × 200; n = 3 per group). A: Control, B: STZ, C: LPS, D: STZ + LPS, E: STZ + LPS + Glib 5 mg/kg. *P < 0.05, **P < 0.01 vs control, ##P < 0.01 vs
STZ + LPS. Values are means ± SEM.
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Figure 5 Glibenclamide did not alter expression of IL-1β and
TNF-α in cardiac tissue by LPS stimulation in streptozotocin
(STZ) diabetic mice. Expression of IL-1β and TNF-α in cardiac tissue
were assessed by ELISA 6 h after LPS injection (15 mg/kg, i.p). In
non-STZ treated mice, LPS stimulation significantly increased both
IL-1β and TNF-α level. In STZ treated mice, LPS stimulation induced
greater levels of IL-1β and TNF-α than those in non-STZ treated
ones, which were not modified by glibenclamide (5 mg/kg, i.g, × 14
d) pretreatment. *P < 0.05, **P < 0.01 vs control, #P < 0.05 vs LPS.
Values are means ± SEM (n = 8 per group).
Figure 6 Glibenclamide inhibited serum IL-1β and TNF-α levels
by LPS stimulation in streptozotocin (STZ) diabetic mice. Serum
IL-1β and TNF-α levels were assessed by ELISA 6 h after LPS injection
(15 mg/kg, i.p). In non-STZ treated mice, LPS stimulation significantly
increased both IL-1β and TNF-α levels. In STZ treated mice, LPS
stimulation induced greater levels of IL-1β and TNF-α than those
in non-STZ treated ones, which were significantly inhibited by
glibenclamide (5 mg/kg, i.g, × 14 d) pretreatment. *P < 0.05, **P < 0.01
vs control; #P < 0.05, ##P < 0.01 vs STZ + LPS, †P < 0.05 vs LPS. Values are
means ± SEM (n = 8-10 per group).
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LPS stimulated cells (Figure 7, n = 6).
Glibenclamide inhibited Nalp3 and Caspase-1 expression
by high glucose and LPS in cultured primary peritoneal
macrophages
Cryopyrin/NALP3/NLRP3 is an essential component
of inflammasomes triggered by microbial ligands,
danger-associated molecular patterns (DAMPs) and
crystals. Inflammasomes activate Caspase-1 for pro-
cessing and secretion of the cytokines IL-1β. Both high
glucose and LPS increased Nalp3 expression (1.37 ±
0.1 fold and 1.67 ± 0.2 fold respectively, P < 0.05). High
glucose + LPS stimulation further increased Nalp3
expression (2.16 ± 0.1 fold, P < 0.05). Glibenclamide
pretreatment significantly reduced the expression of
Nalp3 (1.50 ± 0.3 fold vs 2.16 ± 0.1 fold, P < 0.05). Simi-
lar changes were observed in Caspase-1 expression
(Figure 8, n = 3).Discussion
The major findings of this study are as follows: (i) glib-
enclamide attenuated LPS-induced myocardial injury in
STZ-mice; (ii) glibenclamide reduced serum IL-1β and
TNF-α induced by LPS in STZ-mice; (iii) glibenclamide
inhibited Nalp3 and Caspase-1 expression by LPS + high
glucose stimulation in cultured primary peritoneal mac-
rophages. These together suggested that glibenclamide
might protect against myocardial injury under inflamma-
tion in diabetes.
Sepsis is a common disease with a growing morbidity
around the world. Severe sepsis and systemic inflamma-
tion are the leading causes of mortality in critically ill
patients, resulting from a systemic oxidative-mediated
inflammatory response to severe bacterial infection [34].
It is well known that acute infections lead to difficulty in
controlling blood glucose and that infection is the most
frequently documented cause of ketoacidosis during dia-
betes mellitus [35]. In this study, the endotoxemic mice
Figure 7 Glibenclamide inhibited IL-1β expression by high glucose
and LPS stimulation in primary peritoneal macrophages. IL-1β and
TNF-α in the supernatants of macrophages were assessed by ELISA.
Macrophages were incubated for 24 h with high glucose (33 mM), or
high glucose + LPS (1 μg/ml), or high glucose + LPS + glibenclamide
(100 μM). Cells incubated without drug treatment served as control.
Either high glucose or High glucose + LPS induced significant increase
of both IL-1β and TNF-α, glibenclamide treatment only significantly
inhibited IL-1β expression by high glucose + LPS stimulation. *P< 0.05,
**P< 0.01 vs control; ##P< 0.01 vs Glucose + LPS, †P< 0.05 vs LPS. Values
are means ± SEM (n = 6 per group).
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serum epinephrine level after LPS stimulation, which
was consistent with previous reports [24,36,37]. Pre-
vention or management of sepsis remains a barrier to
the successful care of many surgical and traumatic pa-
tients with diabetes, needing novel therapies urgently
[38]. Type 1 diabetes mellitus is a chronic, multifactorial
autoimmune disease that involves the progressive de-
struction of pancreatic β-cells, ultimately resulting in the
loss of insulin production and secretion [39]. This re-
sponse includes the production of cytokines such as IL-
1β that orchestrate the recruitment of inflammatory cells
to the islets and mediate direct cytotoxic effects on β-
cells [40]. TNF-α is considered to be a possible therapeutic
target because it was up-regulated in multiple rodent-
obesity models and TNF-α blunted insulin signaling in
insulin targeting tissues. It is not only exacerbates inflam-
matory response through acting as a signal amplifier to in-
duce other inflammatory cytokines production, but alsocontributes to myocardial hypertrophy and fibrosis, lead-
ing to left ventricular remodeling and dysfunction [41].
Experimental and clinical studies have suggested that
diabetic state causes a specific diabetic cardiomyopathy in-
dependent of vascular complications. This cardiomyop-
athy is characterized by myocyte hypertrophy and fibrosis
and may be responsible for the high incidence of cardiac
dysfunction and mortality [42]. Ventricles from diabetic
patients show accumulation of glycoproteins, collagen,
and active fibroblasts [43]. Elevated inflammatory cyto-
kines have been found in circulation and in the hearts of
diabetic patients, contributing to heart failure. Cardiac
overexpression of TNF-α has been associated with cardiac
hypertrophy and fibrosis, as well with left ventricular dys-
function [44]. Moreover, up-regulation of inflammatory
cytokines and chemokines by subcutaneous injection of
LPS was significantly more rapid and more pronounced in
the diabetic mice compared with normal mice [45]. These
indicate that cardiac tissue is sensitive to inflammation
and inflammatory response is stronger in diabetic condi-
tion. We observed significant elevations of IL-1β and
TNF-α levels in serum and cardiac tissue upon LPS chal-
lenge in mice, suggesting that both of circulating and local
inflammatory reaction may cause cardiac injury under dia-
betic and septic condition. In addition, we found that glib-
enclamide was able to inhibit the inflammatory cytokines
secreted by peritoneal macrophages after LPS treatment.
Interestingly, glibenclamide only inhibited the increases of
IL-1β but not TNF-α in vitro. We considered this specific
inhibition on IL-1β level by glibenclamide implicated the
involvement of Nalp3, which regulates IL-1β but not
TNF-α. There was an inconsistency of TNF-a data in
serum and in the supernatant. We think that the situation
in vivo is rather complex while the cell model in vitro is
simple. The serum TNF-α levels might be influenced by
many factors. Glibenclamide may lower the serum TNF-
α level in a macrophage-independent manner.
KATP channels are a type of Kir constituted by hetero-
multimers of two kinds of proteins. Each channel is
formed from four pore-forming Kir subunits (Kir 6.1 or
Kir 6.2) complexes with four regulatory sulfonylurea re-
ceptor proteins (SUR1 in neuronal/pancreatic beta cells
or SUR2 in cardiovascular cells). Glibenclamide is a sul-
fonylurea drug which binds to the SUR1 domain with 10
to 500 fold higher affinity than to the SUR2 domains [6].
Previous study demonstrated that glibenclamide was
able to suppress NALP3 activation independently of
KATP [7]. Thus, in this work, we used glibenclamide as
an inhibitor of NALP3.
The mechanism of glibenclamide attenuated LPS-
induced inflammation is not fully elucidated. Transient
receptor potential melastatin 4 (TRPM4), a calcium-
activated non-selective cation channel, is functionally
expressed in the heart. TRPM4 has been linked to
Figure 8 Glibenclamide inhibited Nalp3 and Caspase-1 expression by high glucose and LPS stimulation in primary peritoneal
macrophages. Nalp3 and Caspase-1 in macrophages were measured by western blotting. Macrophages were incubated for 24 h under high
glucose (33 mM), or high glucose + LPS (1 μg/ml), or high glucose + LPS + glibenclamide (100 μM). Cells incubated without drug treatment served
as control. High glucose stimulation significantly increased Caspase-1 expression. Nalp3 and Caspase-1 levels were markedly increased by high
glucose + LPS challenge. Caspase-1 level was further increased by high glucose + LPS compared with LPS group. Both proteins were significantly
inhibited by glibenclamide treatment. *P < 0.05, **P < 0.01 vs control; #P < 0.05, ##P < 0.01 vs Glucose + LPS; ††P < 0.01 vs LPS. Values are means ± SEM
(n = 3 per group).
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against Ca2+ overload by cell membrane depolarization,
modulation of Ca2+ oscillations controlling cytokine
production in T lymphocytes and mast cells, and den-
dritic cell migration [46,47]. Grand et al. reported that
TRPM4 is inhibited by glibenclamide, a modulator of
ATP binding cassette proteins (ABC transporters), such
as the cystic fibrosis transmembrane conductance regula-
tor (CFTR) [48]. It was also reported that TRPM4 inhibi-
tors 9-phenanthrol and glibenclamide could attenuate
LPS-induced endothelial cell death and hypoxia and re-
oxygenation-induced early after depolarizations [49]. Glib-
enclamide is a potent blocker of the ATP-modulated K+
channel in insulin secreting cells and a broadly used anti-
diabetic drug. Interestingly, recent study showed that glib-
enclamide could decrease TNF-α and NF-κB activation
after subarachnoid hemorrhage [50]. Moreover, gliben-
clamide reduced LPS-induced release of IL-1β、TNF-α
and PAI-2 mRNA in a concentration-dependent manner
through reducing the calcium entry by drug-induced
depolarization of hypoxic monocytes in an ex vivo model
of human endotoxinaemia under hypoxaemic conditions
[12]. Koh et al. found that glibenclamide directly reduced
the secretion of IL-1β by bone-marrow-derived macro-
phages in a dose-dependent fashion [51]. In the presentstudy, we further demonstrated that glibenclamide could
decrease serum IL-1β and TNF-α level induced by LPS in
STZ-induced diabetic mice.
Nalp3 is a ‘general sensor’ for danger signals, repre-
senting an important caspase-1-containing inflamma-
somes and is activated by various pathogens [18], and
damage-associated molecules and environmental irri-
tants [40]. Activation of Nalp3 leads to oligomerization
and recruitment of apoptosis-associated speck-like pro-
tein and pro-caspase-1, with auto-cleavage and activa-
tion of Caspase-1. Active Caspase-1 cleaves pro-IL-1β to
active IL-1β, which, when secreted, can exert direct cyto-
toxic effects as well as recruit other inflammatory cells.
In this work, we found that glibenclamide could inhibit
Nalp3 inflammasomes and Caspase-1 induced by LPS +
high glucose stimulation in cultured peritoneal macro-
phages, suggesting that the effects of glibenclamide on
prevention of serum IL-1β and TNF-α might be related
to inhibiting Nalp3 inflammasomes and Caspase-1. The
mechanism how glibenclamide inhibits NALP3 inflamma-
somes and suppresses IL-1β secretion is an intriguing
question. Lamkanfi et al. demonstrated that glibenclamide
could inhibit the assembly of the NALP3 inflammasomes
in response to stimulation with lipopolysaccharide (LPS)
and adenosine triphosphate (ATP) [13]. The ability to
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ent of its inhibitory effect on KATP [13]. The authors specu-
lated that glibenclamide acts the upstream of NALP3 and
the downstream of P2X7 [13]. However, the precise mo-
lecular target of glibenclamide for its inhibitory effect on
NALP3 inflammasome has yet to be identified.
Conclusions
In conclusion, our findings indicate that glibenclamide
could ameliorate myocardial injury and reducing IL-1β
and TNF-α possibly through inhibiting Nalp3 inflam-
masomes and Caspase-1 signaling under LPS-induced
endotoxemia in STZ diabetic mice.
Additional files
Additional file 1: Figure S1. Glibenclamide did not modify body
weight and blood glucose in normal mice. Compared with control,
glibenclamide (5 and 20 mg/kg, i.g, ×14 d) administration did not
change body weight and blood glucose. NS means no significant
difference. Values are means ± SEM (n = 5 per group).
Additional file 2: Figure S2. Injection of LPS caused a decrease in
heart rate and mean arterial pressure, and elevated serum epinephrine
level in mice. Six hours after LPS (15 mg/kg) injection (i.p), heart rate (A)
and mean arterial pressure (B) were measured by MPA-HBBS software.
Serum epinephrine (C) level was assessed by ELISA. Mice were anesthetized
with chloral hydrate (4%), heart rate and mean arterial pressure of
endotoxemic mice decreased during LPS stimulation (heart rate and
mean arterial pressure had been measured for 10 minutes). Serum
epinephrine level was significantly increased in endotoxemic mice
compared with control. *P < 0.05, **P < 0.01. Values are means ± SEM
(n = 5 per group).
Additional file 3: Figure S3. IL-β and TNF-α levels in cardiac tissue and
serum had no significant difference between LPS + STZ + Glibenclamide
(5 mg/kg) group and LPS + STZ + Glibenclamide (20 mg/kg) group. IL-1β
and TNF-α levels in cardiac tissue and serum were assessed by ELISA 6 h
after LPS injection (15 mg/kg, i.p). A: Cardiac tissue, B: Serum. NS means
no significant difference. Values are means ± SEM (n = 6-8 per group).
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